AR086191A1 - Triazolopiridinas - Google Patents

Triazolopiridinas

Info

Publication number
AR086191A1
AR086191A1 ARP120101355A ARP120101355A AR086191A1 AR 086191 A1 AR086191 A1 AR 086191A1 AR P120101355 A ARP120101355 A AR P120101355A AR P120101355 A ARP120101355 A AR P120101355A AR 086191 A1 AR086191 A1 AR 086191A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
halo
nr8r7
group
Prior art date
Application number
ARP120101355A
Other languages
English (en)
Spanish (es)
Inventor
Kosemund Dirk Dr
Wengner Antje Margret Dra
Siemeister Gerhard Dr
Stckigt Detlef Dr
Lienau Philip Dr
Schirok Hartmut Dr
Briem Hans Dr
Schulze Volker Dr
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of AR086191A1 publication Critical patent/AR086191A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP120101355A 2011-04-21 2012-04-20 Triazolopiridinas AR086191A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11163342 2011-04-21
EP11167872 2011-05-27

Publications (1)

Publication Number Publication Date
AR086191A1 true AR086191A1 (es) 2013-11-27

Family

ID=46124297

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101355A AR086191A1 (es) 2011-04-21 2012-04-20 Triazolopiridinas

Country Status (39)

Country Link
US (1) US20140120087A1 (https=)
EP (1) EP2699575B1 (https=)
JP (1) JP5989091B2 (https=)
KR (1) KR20140025470A (https=)
CN (1) CN103608350B (https=)
AP (1) AP3491A (https=)
AR (1) AR086191A1 (https=)
AU (1) AU2012244859B2 (https=)
CA (1) CA2833657A1 (https=)
CL (1) CL2013003044A1 (https=)
CO (1) CO6801751A2 (https=)
CR (1) CR20130539A (https=)
CY (1) CY1116439T1 (https=)
DK (1) DK2699575T3 (https=)
DO (1) DOP2013000244A (https=)
EA (1) EA023766B1 (https=)
EC (1) ECSP13013011A (https=)
ES (1) ES2539265T3 (https=)
GT (1) GT201300254A (https=)
HR (1) HRP20150517T1 (https=)
HU (1) HUE025496T2 (https=)
IL (1) IL228704A0 (https=)
JO (1) JO3040B1 (https=)
MA (1) MA35049B1 (https=)
ME (1) ME02143B (https=)
MX (1) MX348783B (https=)
MY (1) MY164939A (https=)
PE (1) PE20141351A1 (https=)
PH (1) PH12013502169A1 (https=)
PL (1) PL2699575T3 (https=)
PT (1) PT2699575E (https=)
RS (1) RS54044B1 (https=)
SA (1) SA112330466B1 (https=)
SG (1) SG194003A1 (https=)
SI (1) SI2699575T1 (https=)
TW (1) TWI558703B (https=)
UY (1) UY34034A (https=)
WO (1) WO2012143329A1 (https=)
ZA (1) ZA201308707B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013027096A2 (pt) 2011-04-21 2016-12-27 Gilead Sciences Inc compostos de benzotiazol e seu uso farmacêutico
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
CN104284896B (zh) 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
CA2878481A1 (en) 2012-07-10 2014-01-16 Bayer Pharma Aktiengesellschaft Method for preparing substituted triazolopyridines
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014195274A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
JP2016527193A (ja) * 2013-06-07 2016-09-08 バイエル・ファルマ・アクティエンゲゼルシャフト 置換トリアゾロピリジン
SG11201509351UA (en) * 2013-06-10 2015-12-30 Bayer Pharma AG Novel compounds for the treatment of cancer
HK1219879A1 (zh) * 2013-06-11 2017-04-21 Bayer Pharma Aktiengesellschaft 用於治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
RS56034B1 (sr) * 2013-06-11 2017-09-29 Bayer Pharma AG Derivati prolekova supstituisanih triazolopiridina
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
FI3283642T3 (fi) 2015-04-17 2024-01-11 Crossfire Oncology Holding B V Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan
CN109963854B (zh) * 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
NZ780966A (en) 2019-04-18 2026-02-27 Univ Johns Hopkins Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
MX2007001943A (es) 2004-08-17 2007-05-09 Galderma Res & Dev Nuevos compuestos biaromaticos activadores de los receptores del tipo receptor activado del proliferador de peroxisoma (ppar) y su uso en composiciones cosmeticas o farmaceuticas.
JP5336375B2 (ja) * 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
MX2010002115A (es) 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
CA2691448A1 (en) * 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX2010005700A (es) * 2007-11-27 2010-06-11 Cellzome Ltd Amino triazoles como inhibidores pi3k.
SG173610A1 (en) 2009-02-13 2011-09-29 Fovea Pharmaceuticals Sa [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
CN102413831B (zh) 2009-04-29 2014-06-04 拜耳知识产权有限责任公司 取代的咪唑并喹喔啉
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas

Also Published As

Publication number Publication date
AU2012244859A1 (en) 2013-10-31
EA023766B1 (ru) 2016-07-29
AU2012244859B2 (en) 2017-06-08
IL228704A0 (en) 2013-12-31
TW201245194A (en) 2012-11-16
TWI558703B (zh) 2016-11-21
HUE025496T2 (en) 2016-04-28
HK1190398A1 (zh) 2014-07-04
EP2699575B1 (en) 2015-03-25
DK2699575T3 (da) 2015-06-22
CO6801751A2 (es) 2013-11-29
CA2833657A1 (en) 2012-10-26
JP2014511887A (ja) 2014-05-19
ES2539265T3 (es) 2015-06-29
SI2699575T1 (sl) 2015-10-30
PT2699575E (pt) 2015-07-29
JP5989091B2 (ja) 2016-09-07
NZ616456A (en) 2015-09-25
MY164939A (en) 2018-02-15
EA201301181A1 (ru) 2014-08-29
WO2012143329A1 (en) 2012-10-26
MX348783B (es) 2017-06-28
ME02143B (me) 2015-10-20
SG194003A1 (en) 2013-11-29
ECSP13013011A (es) 2013-12-31
RS54044B1 (sr) 2015-10-30
AP2013007182A0 (en) 2013-10-31
AP3491A (en) 2015-12-31
CN103608350A (zh) 2014-02-26
GT201300254A (es) 2015-09-01
EP2699575A1 (en) 2014-02-26
CR20130539A (es) 2013-12-04
HRP20150517T1 (hr) 2015-06-19
US20140120087A1 (en) 2014-05-01
KR20140025470A (ko) 2014-03-04
PE20141351A1 (es) 2014-11-01
DOP2013000244A (es) 2014-03-16
ZA201308707B (en) 2016-07-27
SA112330466B1 (ar) 2015-09-28
CN103608350B (zh) 2015-11-25
CL2013003044A1 (es) 2014-05-02
MA35049B1 (fr) 2014-04-03
JO3040B1 (ar) 2016-09-05
PH12013502169A1 (en) 2014-01-13
CY1116439T1 (el) 2017-02-08
PL2699575T3 (pl) 2015-08-31
MX2013012289A (es) 2013-11-21
UY34034A (es) 2012-11-30

Similar Documents

Publication Publication Date Title
AR086191A1 (es) Triazolopiridinas
AR079166A1 (es) Triazolopiridinas
MX2021014096A (es) Compuestos heterociclicos, metodos de preparacion y usos de estos.
AR112797A1 (es) Inhibidores de kras g12c y métodos para utilizarlos
AR078888A1 (es) Derivados heterociclicos nitrogenados de bencimidazol-imidazol utiles para tratar infecciones por hvc y composiciones farmaceuticas que los comprenden.
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR084412A1 (es) Compuestos de piridina fusionados, utiles como inhibidores de caseina quinasa, y las composiciones farmaceuticas que los contienen
AR091023A1 (es) Inhibidores del nampt
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
AR036365A1 (es) 1,8-naftiridin-4(1h)-onas alquin-aril sustituidas y composiciones farmaceuticas que las contienen
AR081934A1 (es) Compuestos de triazolopiridinas sustituidas, una combinacion farmaceutica que los comprende y el uso de dichos compuestos en la preparacion de medicamentos
AR093740A1 (es) Amidas como inhibidores de pim
AR091093A1 (es) Tienopirimidinas
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
CO6331437A2 (es) Compuestos de pirrolo[2,3-d]pirimidina
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR068846A1 (es) Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
AR090589A1 (es) INHIBIDORES DE b-LACTAMASA ISOXAZOL
AR101106A1 (es) Inhibidores de tirosina quinasa de bruton
AR075253A1 (es) Pirimidinas fusionadas, procesos de preparacion y composiciones farmaceuticas que los contiene.
PE20151860A1 (es) Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd
RU2015121431A (ru) Замещенные производные индол-5-ола и их терапевтическое применение

Legal Events

Date Code Title Description
FB Suspension of granting procedure